These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 25066841

  • 1. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.
    Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants WJ, Cleynen I, Van Steen K, Gils A, Rutgeerts P, Vermeire S, Van Assche G.
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):514-521.e4. PubMed ID: 25066841
    [Abstract] [Full Text] [Related]

  • 2. Factors associated with short- and long-term outcomes of therapy for Crohn's disease.
    Reinisch W, Colombel JF, Sandborn WJ, Mantzaris GJ, Kornbluth A, Adedokun OJ, Miller M, Tang KL, Rutgeerts P, Cornillie F.
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):539-547.e2. PubMed ID: 25245629
    [Abstract] [Full Text] [Related]

  • 3. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 4. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
    Abraham NS, Richardson P, Castillo D, Kane SV.
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.
    Papamichael K, Vande Casteele N, Gils A, Tops S, Hauenstein S, Singh S, Princen F, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M.
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1103-10. PubMed ID: 25478919
    [Abstract] [Full Text] [Related]

  • 6. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.
    Baert F, Drobne D, Gils A, Vande Casteele N, Hauenstein S, Singh S, Lockton S, Rutgeerts P, Vermeire S.
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1474-81.e2; quiz e91. PubMed ID: 24486408
    [Abstract] [Full Text] [Related]

  • 7. Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease.
    Grossi V, Lerer T, Griffiths A, LeLeiko N, Cabrera J, Otley A, Rick J, Mack D, Bousvaros A, Rosh J, Grossman A, Saeed S, Kay M, Boyle B, Oliva-Hemker M, Keljo D, Pfefferkorn M, Faubion W, Kappelman MD, Sudel B, Markowitz J, Hyams JS.
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1748-56. PubMed ID: 25911120
    [Abstract] [Full Text] [Related]

  • 8. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, Komarek A, Lukas M.
    J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
    [Abstract] [Full Text] [Related]

  • 9. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
    Peyrin-Biroulet L, Salleron J, Filippi J, Reenaers C, Antunes O, Filipe V, Louis E, Hébuterne X, Roblin X.
    J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
    [Abstract] [Full Text] [Related]

  • 10. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
    Chauvin A, Le Thuaut A, Belhassan M, Le Baleur Y, Mesli F, Bastuji-Garin S, Delchier JC, Amiot A.
    Dig Liver Dis; 2014 Aug; 46(8):695-700. PubMed ID: 24893686
    [Abstract] [Full Text] [Related]

  • 11. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
    Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P.
    Gastroenterology; 2008 Jun; 134(7):1861-8. PubMed ID: 18440315
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM.
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [Abstract] [Full Text] [Related]

  • 13. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.
    Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, Kopylov U, Eliakim R, Ben-Horin S, ABIRISK consortium.
    Gut; 2014 Aug; 63(8):1258-64. PubMed ID: 24041539
    [Abstract] [Full Text] [Related]

  • 14. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
    Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P.
    Gastroenterology; 2009 Nov; 137(5):1628-40. PubMed ID: 19664627
    [Abstract] [Full Text] [Related]

  • 15. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, Baldassano R, Crandall W, Rosh J, Pfefferkorn M, Otley A, Heyman MB, LeLeiko N, Baker S, Guthery SL, Evans J, Ziring D, Kellermayer R, Stephens M, Mack D, Oliva-Hemker M, Patel AS, Kirschner B, Moulton D, Cohen S, Kim S, Liu C, Essers J, Kugathasan S, Hyams JS, PRO-KIIDS Research Group.
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [Abstract] [Full Text] [Related]

  • 16. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.
    Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, Awadie H, Weiss B, Chowers Y.
    Clin Gastroenterol Hepatol; 2013 Apr; 11(4):444-7. PubMed ID: 23103905
    [Abstract] [Full Text] [Related]

  • 17. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.
    Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A, Drake KA, Hauenstein SI, Lockton S, Deshpande AR, Barkin JS, Singh S, Abreu MT.
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1118-24.e3. PubMed ID: 25562796
    [Abstract] [Full Text] [Related]

  • 18. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
    Kinney T, Rawlins M, Kozarek R, France R, Patterson D.
    Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
    [Abstract] [Full Text] [Related]

  • 19. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.
    Oh EH, Ko DH, Seo H, Chang K, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH.
    World J Gastroenterol; 2017 Feb 28; 23(8):1489-1496. PubMed ID: 28293096
    [Abstract] [Full Text] [Related]

  • 20. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S.
    Gastroenterology; 2015 Jun 28; 148(7):1320-9.e3. PubMed ID: 25724455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.